the potential increase in efficacy by conjugation to radioisotopes and other cellular toxins and the ability to characterize the target with clinical laboratory diagnostics to improve the drug's clinical performance, it is anticipated that current and future antibody therapeutics will find substantial roles...
Celldex draws upon a number of core technologies to design targeted therapeutic candidates that seek to leverage the power of the immune system to fight disease. Our programs encompass validated technologies such as humanized antibodies, important and proprietary disease related molecules and natural human...
Detailed understandings of the molecular interactions that regulate antibody function have afforded investigators the ability to design fit-for-purpose antibody-based therapeutics. This chapter presents an overview of engineering efforts to improve the efficacy and safety of antibody therapeutics....
Monoclonal antibodies are a growing class of targeted cancer therapeutics, characterized by exquisite specificity, long serum half-life, high affinity and immune effector functions. In this review, we outline key advances in the field with a particular focus on recent and emerging classes of engineere...
Monoclonal antibodies are a growing class of targeted cancer therapeutics, characterized by exquisite specificity, long serum half-life, high affinity and immune effector functions. In this review, we outline key advances in the field with a particular focus on recent and emerging classes of engineere...
Invivyd is on a mission to rapidly and continually deliver antibody-based therapies that keep pace with the evolving viral threats
Klakamp, Scott L.Springer New YorkTabrizi, MA, Bornstein, GG, Klakamp, SL (2012) Development of antibody-based therapeutics: translational considerations. Springer, New YorkM.A. Tabrizi, G.G. Bornstein, S.L. Klakamp, Development of antibody-based therapeutics :...
She said antibody-based therapeutics are safe, butclinical trialshave generally shown minimal or no impact on influenza A, and there are currently no approved antibody-based therapies to treat human influenza. "A recent clinical trial used hyperimmune intravenous immunoglobulin (Flu-IVIG)—purified fr...
allow antibody fragment therapeutics to be far more accessible by delivering long lifetime antibody fragment–drug conjugates. This could be achieved by the attachment of an antibody fragment to: (i) a suitable toxic drug; and (ii) a blood serum-stabilizing functionality (for example, PEG, ...
These new agents may have the potential to revolutionize both our thinking and practice in the efforts to research and develop next generation antibody-based therapeutics. Keywords: antibody therapeutics; antibody design; antibody engineering; novel antibody format; next generation of antibody; antibody ...